[Home ] [Archive]   [ فارسی ]  
:: ::
:: Volume 14, Issue 7 (September 2020) ::
Qom Univ Med Sci J 2020, 14(7): 58-68 Back to browse issues page
Estimation of the Economic Burden of Cardiovascular Diseases in Selected Hospitals of Yazd in 2018
Mohsen Pakdaman1 , Sara Gravandi2, Roohollah Askari1 , Milad Shafii1 , Mahdieh Khaleghi Muri3 , Sajjad Bahariniya 4
1- Department of Health Services Management, Health Management and Policy Research Center, School of Public Health, Shahid Sadoughi University of Medical Sciences
2- Department of Health Economics, School of Public Health, Tehran University of Medical Sciences
3- BS in Public Health, School of Public Health, Shahid Sadoughi University of Medical Sciences
4- Masters Student of Health Services Management, Health Management and Policy Research Center, School of Public Health, Shahid Sadoughi University of Medical Sciences , sajjadbahari98@gmail.com
Abstract:   (1926 Views)
Background and Objectives: In Iran, cardiovascular disease is the leading cause of mortality. The economic burden of these diseases imposed on families makes the situation even worse. Health system policymakers need to be aware of the costs of these diseases to make wise decisions regarding the allocation of resources. The present study aimed to estimate the economic burden of cardiovascular disease in selected hospitals in Yazd.
Methods: This cross-sectional study was conducted based on a descriptive-analytical design. The economic burden of cardiovascular disease was estimated using the cost-of-illness method and based on the human capital method. Based on the content and purpose of the current study, the prevalence-based approach was used. A researcher-made questionnaire was used for data collection. The statistical population included patients with cardiovascular disease who referred to the hospitals under study in Yazd. They were selected by random sampling (n=200). The data were analyzed in SPSS and EXCEL software.
Results: 41.5% of patients were male and 58.5% were female. The total direct medical cost was 2,6184,130 Rials and the total non-medical direct medical cost was 11,521,250 Rials for each patient. The economic burden of cardiovascular disease was 16,721,997,317,485 Rials  at a discount rate of 3% ,and a discount rate of 5%, it was reported as 11,819,209,806,581 Rials.
Conclusion: Cardiovascular diseases impose a huge cost on society. The best way to manage these diseases and reduce costs is to change and modify risky behaviors that make the patient invulnerable.
Keywords: Cardiovascular diseases, Cost of disese, Iran, Yazd
Full-Text [PDF 1236 kb]   (814 Downloads)    
Type of Study: Original Article | Subject: مدیریت بهداشتی
Received: 2020/02/11 | Accepted: 2020/09/26 | Published: 2020/10/1
1. World Health Organization. Global status report on non-communicable diseases. Geneva: World Health Organization; 2014. Link
2. Heydarpour F, Akbari Sari A, Mohebali M, Bokaie S. Economic burden of cutaneous and visceral lishmaniasis in Iran in 2013. Iran J Epidemiol 2017;13(1):1-13. Link
3. Javadi M, Asgari H, Yaghoobbi M, Tavazohi H. Self-assessment of the non-communicable disease surveillance system in Medical University of Isfahan based on the model suggested by the World Health Organization. J Sch Public Health Instit Public Health Res 2010;8(3):47-60. (In Persian) Link
4. Karimi S, Javadi M, Jafarzadeh F. Economic burden and costs of chronic diseases in Iran and the World. Health Inform Manag 2012;8(7):984-96. (In Persian) Link
5. World Health Organization. Preventing chronic diseases: a vital investment: WHO global report. Geneva: World Health Organization; 2005. Link
6. Cost of non-communicable diseases. The European Commission's Science and Knowledge Service. Available at: URL: www.ifpma.org/fileadmin/.../2_PFCD-Cost-of-NCDs_8.5x11.pdf; 2011. Link
7. DeVol R, America AU. The economic burden of chronic disease-charting a new course to save lives and increase productivity and economic growth. New Jersey: Milken Institute; 2007. Link
8. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442. PMID: 17132052 [DOI:10.1371/journal.pmed.0030442]
9. World Health Organization, World Economic Forum. From burden to "Best Buys": reducing the economic impact of non-communicable diseases in low-and middle-income countries. Geneva: World Health Organization; 2011. Link
10. World Health Organization. The impact of chronic disease in the Islamic Republic of Iran. Geneva: World Health Organization; 2012. Link
11. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007;7(1):32-7. PMID: 17971195 [DOI:10.1186/1471-2261-7-32]
12. Evans DB, Tandon A, Murray CJ, Lauer JA. Comparative efficiency of national health systems: cross national econometric analysis. BMJ 2001;323(7308):307-10. PMID: 11498486 [DOI:10.1136/bmj.323.7308.307]
13. Hutubessy RC, Baltussen RM, Torres-Edejer TT, Evans DB. Generalised cost-effectiveness analysis: an aid to decision making in health. Appl Health Econ Health Policy 2002;1(2):89-95. Link
14. Lakić D, Tasić L, Kos M. Economic burden of cardiovascular diseases in Serbia. Vojnosanit Pregl 2014;71(2):137-43. PMID: 24665570 [DOI:10.2298/VSP1402137L]
15. Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15(8):883-93. PMID: 20667966 [DOI:10.1634/theoncologist.2010-0005]
16. Stommel M, Given CW, Given BA. The cost of cancer home care to families. Cancer 1993;71(5):1867-74. Link https://doi.org/10.1002/1097-0142(19930301)71:5<1867::AID-CNCR2820710525>3.0.CO;2-7 [DOI:10.1002/1097-0142(19930301)71:53.0.CO;2-7]
17. Karan A, Engelgau M, Mahal A. The household-level economic burden of heart disease in India. Trop Med Int Health 2014;19(5):581-91. PMID: 24612174 [DOI:10.1111/tmi.12281]
18. Ebadifard Azar F, Rezapour A. Economic evaluation. 1st ed. Tehran. The Organization for Researching and Composing University Textbooks in the Humanities (SAMT); 2014. Link
19. Weinstein MC, Russell LB, Gold MR, Siegel JE. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996. Link
20. Geravandi S, Pakdaman M. Comment on: estimating economic burden of cancer deaths attributable to smoking in Iran in 2012. J Res Health Sci 2016;16(2):96-7. PMID: 27497778
21. Emamgholipour S, Sari AA, Pakdaman M, Geravandi S. Economic burden of cardiovascular disease in the southwest of Iran. Int Cardiovasc Res J 2018;12(1):1-6. Link
22. Larijani B, Fakhrzadeh H, Mohaghegh M, Pourebrahim R, Akhlaghi MR. Burden of coronary heart disease on the Iranian oil industry (1999-2000). East Mediterr Health J 2003;9(5-6):904-10. PMID: 16450520
23. Raghfar H, Sargazi N, Mehraban S, Akbarzadeh MA, Vaez Mahdavi MR, Vahdati Manesh Z. The economic burden of coronary heart disease in Iran: a bottom-up approach in 2014. J Ardabil Univ Med Sci 2018;18(3):341-56. Link [DOI:10.29252/jarums.18.3.341]
24. Emamgholipour S, Akbari Sari A, Geravandi S, Mazrae H. Estimation of out-of-pocket and catastrophic expenditures among patients with cardiovascular diseases in Khuzestan. J Payavard Salamat 2017;11(3):297-307. (In Persian) Link
25. Chang HS, Kim HJ, Nam CM, Lim SJ, Jang YH, Kim S, et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health 2012;45(5):291-300. PMID: 23091654 [DOI:10.3961/jpmph.2012.45.5.291]
26. Łyszczarz B. Indirect costs and public finance consequences of heart failure in Poland, 2012-2015. BMC Public Health 2018;18(1):1130. PMID: 30231932 [DOI:10.1186/s12889-018-6034-0]
27. Walker IF, Garbe F, Wright JM, Newell I, Athiraman N, Khan N, et al. The economic costs of cardiovascular disease, diabetes mellitus, and associated complications in south Asia: a systematic review. Value Health Reg Issues 2018;15:12-26. PMID: 29474174 [DOI:10.1016/j.vhri.2017.05.003]
28. Kotseva K, Gerlier L, Sidelnikov E, Kutikov L, Lamotte M, Amarenco P, et al. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. Eur J Prev Cardiol 2019;26(11):1150-7. PMID: 30955367 [DOI:10.1177/2047487319834770]
29. Banefelt J, Hallberg S, Fox KM, Mesterton J, Paoli CJ, Johansson G, et al. Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden. Eur J Health Econ 2016;25(17):1117-24. PMID: 26607457 [DOI:10.1007/s10198-015-0749-y]
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pakdaman M, Gravandi S, Askari R, Shafii M, Khaleghi Muri M, Bahariniya S. Estimation of the Economic Burden of Cardiovascular Diseases in Selected Hospitals of Yazd in 2018. Qom Univ Med Sci J. 2020; 14 (7) :58-68
URL: http://journal.muq.ac.ir/article-1-2743-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 7 (September 2020) Back to browse issues page
مجله دانشگاه علوم پزشکی قم Qom University of Medical Sciences Journal
Persian site map - English site map - Created in 0.07 seconds with 30 queries by YEKTAWEB 4366